The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756 | Terminated Phase 2 Results DMC

• 1 other identifier: 1303010802
• Study Type: interventional
• Target: 95
• Locations: 1 country
• Sites: 4

Brief Summary

The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia. The specific hypotheses to be tested are to determine if LY500307 is safe and well tolerated in this population and whether it elicits a sufficient efficacy signal to be advanced for further testing in schizophrenia. A two-stage Phase 1b/Phase 2a adaptive ("drop the inferior dose") experimental design is ongoing that combines three studies (clinical dose optimization, cortical target engagement confirmation and efficacy and safety assessment) into a single clinical trial. Stage 1 was conducted in year 1 and Stage 2 will be conducted in years 2 and 3. The goal of Stage 1 was to identify and advance the highest dose that did not demonstrate a safety signal and had target selectivity as determined by lack of TT suppression. This criteria was fulfilled at both doses, the larger of the two (75 mg/day dose) was advanced to Stage 2. Furthermore, there was no suggestion of ERα receptor activation (i.e., no pattern of TT decreases or feminization AEs) at either dose (25 mg/day and 75 mg/day). A third arm of 150 mg/day was added to Stage 2 for evaluation. Stage 2 results in the following three arms: placebo, 75 mg/day and 150 mg/day. The goals of Stage 2 are to further assess LY500307 doses for safety and target selectivity, confirm cortical target engagement and assess efficacy. Primary Aim 1: To determine if LY500307 demonstrates cortical target engagement as assessed by fMRI/N-back in frontal-parietal regions. Secondary measures of target engagement are fMRI episodic memory, Pseudo-Continuous Arterial Spin Labeling, Mismatch Negativity/evoked response potentials, Auditory Steady State Response, Auditory P300 and Quantitative EEG (QEEG). Primary Aim 2: To determine if LY500307 is superior to placebo for one or more of the primary efficacy endpoints: negative symptoms (Negative Symptom Assessment Scale - 16-item total score), working memory (the composite score for the Letter Number Sequencing and Spatial Span tests) and verbal memory (Hopkins Verbal Learning Test). Primary Aim 3: To determine if LY500307 reduces total testosterone (TT) plasma concentrations, which is indicative of loss of selectivity for ERβ and engagement of ERα, using the following criteria: Decrease in TT plasma concentrations of 50% from baseline in 50% of subjects per arm treated for two consecutive post-randomization values with LY500307 in Stage 1 and Stage 2 of the trial. Primary Aim 4: To assess the safety of LY500307 by determining if there are SAEs, AEs "probably related to study drug," QTc prolongation, TT suppression (50% reduction from baseline) and to evaluate for other safety signals.

Conditions

Schizophrenia

Keywords

schizophrenia; Estrogen receptor agonist; cognitive impairment; negative symptoms

Outcome Measures

Primary Outcomes (6)

• Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score

  The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 "anchors," is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview.

  Baseline, week 2, week 4, week 6, week 8

• Working Memory Composite Score Changes

  Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance.

  Baseline, week 2, week 4, week 6, week 8

• Verbal Learning Composite Score Changes

  Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance. The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance.

  Baseline, week 2, week 4, week 6, week 8

• Number of Subjects With Total Testosterone Reduction

  Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values

  week 2, week 4, week 8

• Number of Subjects With QTc Prolongation

  Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases

  Week 4, Week 8

• Cortical Target Engagement

  To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI.

  Baseline, 8 weeks

Study Arms (4)

LY500307 150mg

EXPERIMENTAL

LY500307 150mg

Drug: LY500307 150mg

placebo

PLACEBO COMPARATOR

placebo 6 pills of inactive drug

Drug: Placebo

LY500307 75mg

EXPERIMENTAL

LY500307 75mg

Drug: LY500307 75mg

LY500307 25mg

EXPERIMENTAL

LY500307 25mg

Drug: LY500307 25mg

Interventions

LY500307 150mg DRUG

LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks

LY500307 150mg

LY500307 75mg DRUG

LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks

LY500307 75mg

Placebo DRUG

6 placebo capsules daily for 8 weeks

placebo

LY500307 25mg DRUG

LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks

LY500307 25mg

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• to 65 years of age at study entry
• Male
• DSM IV-TR diagnosis of schizophrenia as confirmed by Structured Clinical Interview for DSM-IV-TR (SCID)
• Outpatient or inpatient status
• Mild to moderate overall disease severity as defined by a CGI-S score of less than or equal to 4 (moderately ill) at randomization
• Moderate levels of negative symptoms as defined by a PANSS negative symptom sub-score greater than or equal to 11.
• Clinical stability as defined by:
• No exacerbation of illness leading to an intensification of treatment in the opinion of the investigator within four weeks prior to randomization, and
• No change in antipsychotic medication for at least four weeks prior to randomization

You may not qualify if:

• Subjects with current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, COPD, severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic, renal gastroenterologic, respiratory, endocrinologic, neurologic, hematologic, or infectious diseases
• Known or suspected history of prostate cancer, breast cancer, or other clinically significant neoplastic disease (other than squamous cell or basal cell carcinoma of skin)
• Known or suspected history of deep venous thrombosis, stroke, venous thromboembolism, pulmonary embolism, paresis or paralysis that may be thrombogenic in origin
• Subjects currently receiving testosterone replacement therapy or drugs that influence the hypothalamus-pituitary-gonadal axis.
• Subjects who have clinically significant extrapyramidal signs (EPS) as defined by a score of \>20 on the Simpson-Angus Scale (SAS)
• Clinically significant electrocardiogram (ECG) abnormality, including, but not limited to, a corrected QT interval (Bazett's; QTcB) \>450 msec. Repeat ECGs may be conducted at the discretion of the principal investigator.
• Subjects with known medical history of Human Immunodeficiency Virus positive (HIV+) status
• Subjects with an active seizure disorder
• Subjects with implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or other contraindication to undergoing an MRI scan
• Known IQ less than 70 based on medical history
• Current DSM IV-TR diagnosis of substance dependence (excluding caffeine and nicotine)
• Subjects who test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B surface antigen (HBsAg) with or without positive Hepatitis B core total antibody
• Subjects with moderate to severe renal impairment as defined by creatinine clearance (CrCl) \< 60 ml/min (measured by the Cockcroft-Gault equation) at screening. Repeat evaluation may be conducted at the discretion of the Principal Investigator.
• Subjects with hepatic impairment as defined by liver transaminases or total bilirubin \> 3 × upper limit of normal (ULN). Repeat evaluation may be conducted at the discretion of the Principal Investigator.
• Subjects considered a high risk for suicidal acts - active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening

Sponsors & Collaborators

• Indiana University: lead
• Eli Lilly and Company: collaborator

Study Sites (4)

Indiana University Center for NeuroImaging

Indianapolis, Indiana, 46202, United States

Location

IU Biostatistics

Indianapolis, Indiana, 46202, United States

Location

Prevention and Recovery Center for Early Psychosis

Indianapolis, Indiana, 46202, United States

Location

Larue D Carter Memorial Hospital

Indianapolis, Indiana, 46222, United States

Location

MeSH Terms

Conditions

Schizophrenia; Cognitive Dysfunction

Interventions

erteberel

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Cognition Disorders; Neurocognitive Disorders

Results Point of Contact

• Title: Dr. Alan Breier
• Organization: Indiana University

abreier@iupui.edu

3178808495

Study Officials

• Alan Breier, MD

  Indiana University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Psychiatrist

Study Record Dates

• First Submitted: May 20, 2013
• First Posted: June 11, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2017
• Study Completion: December 1, 2017
• Last Updated: July 2, 2019
• Results First Posted: July 2, 2019

Record last verified: 2019-06

Locations

US (4)